Home » Stocks » NTLA

Intellia Therapeutics, Inc. (NTLA)

Stock Price: $67.41 USD 0.08 (0.12%)
Updated Apr 20, 2021 4:00 PM EDT - Market closed
After-hours: $65.60 -1.81 (-2.69%) Apr 20, 6:23 PM
Market Cap 4.56B
Revenue (ttm) 57.99M
Net Income (ttm) -134.23M
Shares Out 55.99M
EPS (ttm) -2.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 20
Last Price $67.41
Previous Close $67.33
Change ($) 0.08
Change (%) 0.12%
Day's Open 66.46
Day's Range 63.66 - 68.98
Day's Volume 819,468
52-Week Range 12.32 - 92.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

A "sell" rating is one thing, but a price target barely half of the Thursday close? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it.

Other stocks mentioned: CRSP, EDIT
4 days ago - InvestorPlace

CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology ...

1 week ago - GlobeNewsWire

The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.

Other stocks mentioned: BEAM, CLLS, CRSP, EDIT
2 weeks ago - InvestorPlace

CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology ...

3 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) will present the first preclinical data set on its novel cytosine deaminase base editor technology at the s...

3 weeks ago - GlobeNewsWire

The stock price of Intellia Therapeutics, a biotechnology company developing treatments using a CRISPR gene-editing system, has seen a solid 15% rise over the last five trading days, while it is up 6% o...

1 month ago - Forbes

Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players. The post Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT...

Other stocks mentioned: BEAM, BLUE, CRSP, EDIT
1 month ago - InvestorPlace

- Demonstrates the promise of Intellia's proprietary non-viral delivery system for in vivo genome editing of tissues outside the liver, with applications to inherited blood disorders such as sickle cell...

1 month ago - GlobeNewsWire

Our indicative theme of Gene Editing stocks is down by about 24% year-to-date, compared to the S&P 500 which has remained almost flat over the same period. The recent sell-off comes on the back of risin...

Other stocks mentioned: EDIT
1 month ago - Forbes

Intellia (NTLA) miss earnings and revenues estimates in the fourth quarter of 2020. Stock up.

1 month ago - Zacks Investment Research

CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology b...

1 month ago - GlobeNewsWire

Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology b...

2 months ago - GlobeNewsWire

Intellia Therapeutics (NTLA) is likely to discuss the progress of its pipeline candidate on its fourth-quarter earnings call.

2 months ago - Zacks Investment Research

Our indicative theme of Gene Editing Stocks is up by about 187% since the end of 2018 and by about 5% year-to-date. Gene editing has received more attention this year, as scientists used the technology ...

Other stocks mentioned: VRTX
2 months ago - Forbes

It's been a long, long journey… but we are finally at the point where genomics is ready to change the world. The post A Highly Specialized Gene Editing Stock with a Clear Pathway to Big Gains appeared f...

2 months ago - InvestorPlace

Gene-editing technology is used to insert, edit, or delete a gene from an organism's genome, and shows promise in treating medical conditions ranging from cancer to rare genetic conditions. Our indicati...

Other stocks mentioned: EDIT
2 months ago - Forbes

Among the public companies that made the BioSpace list of the top up and coming life sciences firms in 2019 and 2020, the majority have seen gains in their share prices. Given this metric, investors mig...

Other stocks mentioned: BEAM, CRSP, EDIT, SWTX
3 months ago - GuruFocus

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared first on In...

Other stocks mentioned: BEAM, CLLS, CLXT, CRSP, EDIT, SGMO
3 months ago - InvestorPlace

Gene editing has emerged as a promising biotech theme. The technology is used to insert, edit, or delete a gene from an organism's genome, helping to replace the defective genes responsible for a medica...

Other stocks mentioned: EDIT, CRSP
3 months ago - Forbes

A leading portfolio manager recently told Bloomberg Television that gene-editing companies may turn out to be better investment opportunities than Tesla Inc. (NASDAQ:TSLA).

Other stocks mentioned: CRSP, EDIT
3 months ago - GuruFocus

Shares of Intellia were up as the update on its gene-editing drugs excited investors. The news also pushed up stocks of companies making gene-editing drugs, FATE, CRSP, EDIT, using CRISPR technology.

3 months ago - Zacks Investment Research

Investors are looking forward to what could be a great year for the biotechnology company.

3 months ago - The Motley Fool

Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021

Other stocks mentioned: CRSP, EDIT
3 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology b...

3 months ago - GlobeNewsWire

Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.

Other stocks mentioned: CBAY, EDIT, MRNS, VRTX
3 months ago - Zacks Investment Research

The gene-editing stocks are being pulled down by a broader biotech sell-off.

Other stocks mentioned: CRSP, EDIT
3 months ago - The Motley Fool

Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.

Other stocks mentioned: FATE, MRNA, MRSN, RARE
3 months ago - Zacks Investment Research

Intellia is overshadowed a bit by its cousins Editas & CRISPR Therapeutics, however Intellia has a rich pipeline that looks to be focused on a few opportunities outside of its competition. The stock has...

3 months ago - Seeking Alpha

Crispr Therapeutics, Editas Medicine and Intellia Therapeutics were ablaze Monday as all three genetics stocks touched highs. Uniqure stock fell on a clinical hold for its gene therapy test.

Other stocks mentioned: EDIT, QURE
3 months ago - Investors Business Daily

Demonstrates modularity of Intellia's in vivo liver insertion technology to durably restore protein, compared to traditional gene therapy

4 months ago - GlobeNewsWire

In the Century of Biology, it pays to own the future of curing disease at the root.

Other stocks mentioned: CRSP, EDIT, SGMO, VRTX
4 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), is presenting new preclinical data in support of NTLA-5001, the company's wholly owned Wilms' Tumor 1 (WT1)...

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology b...

4 months ago - GlobeNewsWire

Intellia (NTLA) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology b...

4 months ago - GlobeNewsWire

Funding from the Bill & Melinda Gates Foundation to develop safe, scalable and accessible non-viral treatments for sickle cell patients

5 months ago - GlobeNewsWire

NTLA-2001: First single-course therapy that potentially halts and reverses ATTR progression

5 months ago - GlobeNewsWire

Intellia Therapeutics, Inc.'s (NTLA) CEO John Leonard on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology b...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology b...

5 months ago - GlobeNewsWire

NTLA-2001: First single-course therapy that potentially halts and reverses ATTR

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Today, Jennifer Doudna, Ph.D., one of Intellia Therapeutics, Inc.’s scientific co-founders, was awarded the 2020 Nobel Prize in Chemistry for the deve...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology b...

6 months ago - GlobeNewsWire

In Vivo g ene k nockout and i nsertion data to be presented at O TS Annual Meeting  highlight modularity of Intellia’s platform and potential for variety of single-course therapies ,  with com...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technolog...

6 months ago - GlobeNewsWire

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a preclinical-stage genome editing company focusing on developing novel therapeutics using the genome-editing process known as CRISPR/Cas9.

6 months ago - Seeking Alpha

Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?

Other stocks mentioned: CRSP, EDIT, SGMO, VRTX
7 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technolog...

7 months ago - GlobeNewsWire

Intellia Therapeutics (NTLA) CEO John Leonard on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

About NTLA

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 ... [Read more...]

Industry
Biotechnology
IPO Date
May 6, 2016
CEO
John Leonard
Employees
312
Stock Exchange
NASDAQ
Ticker Symbol
NTLA
Full Company Profile

Financial Performance

In 2020, NTLA's revenue was $57.99 million, an increase of 34.55% compared to the previous year's $43.10 million. Losses were -$134.23 million, 34.9% more than in 2019.

Financial Statements

Analyst Forecasts

According to 14 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is 78.46, which is an increase of 16.39% from the latest price.

Price Target
$78.46
(16.39% upside)
Analyst Consensus: Buy